Finance And Related Services Tenders

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Rotigotine (N04bc09) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Fondaparinux (B01ax05) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Sarilumab (L04ac14) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Everolimus (L04aa18) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Tocilizumab (L04ac07) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Bexarotene (L01xf03) as Part of a So-Called Open House Model.

Oh-Biologika-2023-29 - Tocilizumab

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Adefovir Dipivoxil

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Tofacitinib

REZ NORD 45ind JC Vorpommern-Greifswald Süd (201-23-45ind-30216)